We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GE HealthCare Q4 Earnings Beat Estimates, Sales Miss, Net Margin Rises
Read MoreHide Full Article
GE HealthCare (GEHC - Free Report) reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.45, which beat the Zacks Consensus Estimate of $1.26 by 15.1%. Also, the bottom line improved 22.9% year over year.
GAAP EPS in the quarter was $1.57, up 78.4% from the year-ago level.
Shares of GEHC gained 0.7% during pre-market trading following better-than-expected earnings in the fourth quarter. The company’s shares have gained 3% in the past six months compared with the industry’s 12.8% growth. The S&P 500 Index has increased 11.8% in the same period.
Image Source: Zacks Investment Research
Revenue Details
The company reported revenues of $5.32 billion, up 2% year over year on a reported as well as organic basis. The top line, however, missed the Zacks Consensus Estimate by 0.2%. Total company orders increased 6% organically year over year.
Revenues were driven by strength in the U.S. market across all segments, especially in Advanced Visualization Solutions and Pharmaceutical Diagnostics segments.
Full-Year Details
For full-year 2024, GEHC reported revenues of $19.67 billion, up 1% year over year on a reported as well as organic basis. Adjusted EPS improved 14.2% to $4.49.
Segmental Details
Imaging
Revenues from this segment totaled $2.39 billion, flat year over year reportedly as well as organically.
Segment EBIT was $302 million, up 19% year over year.
Advanced Visualization Solutions
Revenues totaled $1.44 billion, up 4% year over year reportedly as well as organically.
Segment EBIT was $374 million, up 15% year over year.
Patient Care Solutions
Revenues amounted to $827 million, flat year over year reportedly as well as organically.
Segment EBIT was $106 million, down 4% year over year.
Pharmaceutical Diagnostics
Revenues totaled $646 million, up 9% year over year as well as on an organic basis.
Segment EBIT was $212 million, up 47% year over year.
Margins
Net income margin was 13.5%, up 580 basis points from the prior-year level, primarily due to benefits from productivity and pricing.
Cumulative cash flow from operating activities at the end of the fourth quarter was $1.96 billion compared with $2.1 billion a year ago.
Financial Position
GEHC exited the fourth quarter with cash, cash equivalents and investments of $2.89 billion compared with $3.57 billion in the previous quarter.
Total assets decreased to $33.08 billion from $33.86 billion on a sequential basis.
2025 Guidance
GE HealthCare provided its earnings and organic revenue guidance for 2025.
The company expects adjusted EPS to be in the range of $4.61-$4.75, indicating growth of 3-6% year over year. Revenues are anticipated to grow 2-3% organically, reflecting continued demand for its products and services. The Zacks Consensus Estimate for EPS and revenues is pegged at $4.65 billion and $20.38 billion, respectively.
GE HealthCare Technologies Inc. Price, Consensus and EPS Surprise
CAH’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 9.64%. Its shares have gained 19.5% in the past six months compared with the industry’s 4.1% growth.
Masimo, carrying a Zacks Rank of 2 at present, has an estimated growth rate of 6.6% for 2025. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 17.10%. Masimo’s shares have risen 44.9% over the past six months compared with the industry’s 1.7% growth.
Merit Medical, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 12%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.42%. Its shares have risen 19.3% over the past six months compared with the industry’s 4.1% growth.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GE HealthCare Q4 Earnings Beat Estimates, Sales Miss, Net Margin Rises
GE HealthCare (GEHC - Free Report) reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.45, which beat the Zacks Consensus Estimate of $1.26 by 15.1%. Also, the bottom line improved 22.9% year over year.
GAAP EPS in the quarter was $1.57, up 78.4% from the year-ago level.
Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.
Shares of GEHC gained 0.7% during pre-market trading following better-than-expected earnings in the fourth quarter. The company’s shares have gained 3% in the past six months compared with the industry’s 12.8% growth. The S&P 500 Index has increased 11.8% in the same period.
Image Source: Zacks Investment Research
Revenue Details
The company reported revenues of $5.32 billion, up 2% year over year on a reported as well as organic basis. The top line, however, missed the Zacks Consensus Estimate by 0.2%. Total company orders increased 6% organically year over year.
Revenues were driven by strength in the U.S. market across all segments, especially in Advanced Visualization Solutions and Pharmaceutical Diagnostics segments.
Full-Year Details
For full-year 2024, GEHC reported revenues of $19.67 billion, up 1% year over year on a reported as well as organic basis. Adjusted EPS improved 14.2% to $4.49.
Segmental Details
Imaging
Revenues from this segment totaled $2.39 billion, flat year over year reportedly as well as organically.
Segment EBIT was $302 million, up 19% year over year.
Advanced Visualization Solutions
Revenues totaled $1.44 billion, up 4% year over year reportedly as well as organically.
Segment EBIT was $374 million, up 15% year over year.
Patient Care Solutions
Revenues amounted to $827 million, flat year over year reportedly as well as organically.
Segment EBIT was $106 million, down 4% year over year.
Pharmaceutical Diagnostics
Revenues totaled $646 million, up 9% year over year as well as on an organic basis.
Segment EBIT was $212 million, up 47% year over year.
Margins
Net income margin was 13.5%, up 580 basis points from the prior-year level, primarily due to benefits from productivity and pricing.
Cumulative cash flow from operating activities at the end of the fourth quarter was $1.96 billion compared with $2.1 billion a year ago.
Financial Position
GEHC exited the fourth quarter with cash, cash equivalents and investments of $2.89 billion compared with $3.57 billion in the previous quarter.
Total assets decreased to $33.08 billion from $33.86 billion on a sequential basis.
2025 Guidance
GE HealthCare provided its earnings and organic revenue guidance for 2025.
The company expects adjusted EPS to be in the range of $4.61-$4.75, indicating growth of 3-6% year over year. Revenues are anticipated to grow 2-3% organically, reflecting continued demand for its products and services. The Zacks Consensus Estimate for EPS and revenues is pegged at $4.65 billion and $20.38 billion, respectively.
GE HealthCare Technologies Inc. Price, Consensus and EPS Surprise
GE HealthCare Technologies Inc. price-consensus-eps-surprise-chart | GE HealthCare Technologies Inc. Quote
Zacks Rank and Stocks to Consider
GEHC carries a Zacks Rank #4 (Sell) at present.
Some better-ranked stocks from the medical industry are Cardinal Health (CAH - Free Report) , Masimo (MASI - Free Report) and Merit Medical Systems (MMSI - Free Report) .
Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 5.1% for fiscal 2025. You can seethe complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
CAH’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 9.64%. Its shares have gained 19.5% in the past six months compared with the industry’s 4.1% growth.
Masimo, carrying a Zacks Rank of 2 at present, has an estimated growth rate of 6.6% for 2025. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 17.10%. Masimo’s shares have risen 44.9% over the past six months compared with the industry’s 1.7% growth.
Merit Medical, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 12%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.42%. Its shares have risen 19.3% over the past six months compared with the industry’s 4.1% growth.